Bolt Biotherapeutics, Inc.
BOLT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001641281
In the last 90 days, Bolt Biotherapeutics, Inc. insiders filed 2 open-market purchases and 3 sales; 23 institutions reported holding it in 13F filings for Q2 2026, worth $2.31M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Bolt Biotherapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- −1 vs. Q2 2025
- Shares held
- 804.0K
- −83.5K (−9.4%) vs. Q2 2025
- Total value
- $4.28M
- −$819.0K (−16.1%) vs. Q2 2025
- New holders
- 3
- 2 more added
- Sold out
- 4
- 9 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BOLT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 23 | $2.31M |
| Q1 2026 | 24 | $2.49M |
| Q4 2025 | 21 | $3.30M |
| Q3 2025 | 24 | $4.28M |
| Q2 2025 | 25 | $5.10M |
| Q1 2025 | 30 | $7.33M |
| Q4 2024 | 38 | $9.99M |
| Q3 2024 | 32 | $12.2M |
| Q2 2024 | 37 | $17.0M |
| Q1 2024 | 39 | $33.6M |
| Q4 2023 | 40 | $27.0M |
| Q3 2023 | 35 | $25.5M |
| Q2 2023 | 40 | $32.1M |
| Q1 2023 | 41 | $32.4M |
| Q4 2022 | 44 | $26.8M |
| Q3 2022 | 56 | $39.7M |
| Q2 2022 | 62 | $54.8M |
| Q1 2022 | 66 | $79.3M |
| Q4 2021 | 62 | $164.6M |
| Q3 2021 | 72 | $449.1M |
| Q2 2021 | 61 | $513.8M |
| Q1 2021 | 70 | $1.04B |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Bolt Biotherapeutics, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Salem Investment Counselors Inc | 2 | $11 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 3 | $16 | 0.00% | −180−98.4% | Reduced |
| Barclays PLC | 6 | $32 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 10 | $53 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 31 | $165 | 0.00% | −251−89.0% | Reduced |
| JPMorgan Chase & Co | 42 | $223 | 0.00% | −1−2.3% | Reduced |
| Tower Research Capital LLC (TRC) | 259 | $1.38K | 0.00% | −136−34.4% | Reduced |
| Morgan Stanley | 3,128 | $16.6K | 0.00% | −451−12.6% | Reduced |
| BlackRock, Inc. | 9,711 | $51.7K | 0.00% | −839−8.0% | Reduced |
| DRW Securities, LLC | 12,322 | $65.6K | 0.00% | +12,322 | New |
| Squarepoint Ops LLC | 14,836 | $78.9K | 0.00% | +2,448+19.8% | Added |
| Shay Capital LLC | 15,958 | $84.9K | 0.02% | +15,958 | New |
| Susquehanna International Group, LLP | 16,642 | $88.5K | 0.00% | +16,642 | New |
| Geode Capital Management, LLC | 18,533 | $98.6K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 28,625 | $152.3K | 0.00% | +10,300+56.2% | Added |
| Pfizer Inc | 31,305 | $166.5K | 0.04% | 00.0% | Unchanged |
| Vanguard Group Inc | 34,231 | $182.1K | 0.00% | −24,253−41.5% | Reduced |
| Board of Trustees of The Leland Stanford Junior University | 35,978 | $191.4K | 0.02% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 48,830 | $259.8K | 0.03% | −3,626−6.9% | Reduced |
| Nan Fung Group Holdings Ltd | 58,347 | $310.4K | 0.52% | 00.0% | Unchanged |
| Tang Capital Management LLC | 66,879 | $355.8K | 0.01% | −100,000−59.9% | Reduced |
| Pivotal bioVenture Partners Investment Advisor LLC | 94,573 | $503.1K | 0.29% | 00.0% | Unchanged |
| Sofinnova Investments, Inc. | 137,721 | $732.7K | 0.04% | 00.0% | Unchanged |
| Vivo Capital, LLC | 176,064 | $936.7K | 0.08% | 00.0% | Unchanged |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −10,823−100.0% | Sold out |
| GWM Advisors LLC | 0 | $0 | 0.00% | −483−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −121−100.0% | Sold out |
| Danske Bank A/S | 0 | $0 | 0.00% | −1−100.0% | Sold out |